Mitochondrially Targeted Tamoxifen As Anticancer Therapy: Case Series of Patients with Renal Cell Carcinoma Treated in a Phase I/Ib Clinical Trial

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2023 Oct 3

PMID 37786538

Authors

Zuzana Bielcikova

Lukas Werner

Jan Stursa

Vladimir Cerny

Ludmila Krizova

Jan Spacek

Stanislav Hlousek

Michal Vocka

Olga Bartosova

Michal Pesta

Katarina Kolostova

Petr Klezl

Vladimir Bobek

Jaroslav Truksa

Sona Stemberkova-Hubackova

Lubos Petruzelka

Pavel Michalek

Jiri Neuzil

Affiliations

Soon will be listed here.

Abstract

Mitochondrially targeted anticancer drugs (mitocans) that disrupt the energy-producing systems of cancer are emerging as new potential therapeutics. Mitochondrially targeted tamoxifen (MitoTam), an inhibitor of mitochondrial respiration respiratory complex I, is a first-in-class mitocan that was tested in the phase I/Ib MitoTam-01 trial of patients with metastatic cancer. MitoTam exhibited a manageable safety profile and efficacy; among 37% (14/38) of responders, the efficacy was greatest in patients with metastatic renal cell carcinoma (RCC) with a clinical benefit rate of 83% (5/6) of patients. This can be explained by the preferential accumulation of MitoTam in the kidney tissue in preclinical studies. Here we report the mechanism of action and safety profile of MitoTam in a case series of RCC patients. All six patients were males with a median age of 69 years, who had previously received at least three lines of palliative systemic therapy and suffered progressive disease before starting MitoTam. We recorded stable disease in four, partial response in one, and progressive disease (PD) in one patient. The histological subtype matched clear cell RCC (ccRCC) in the five responders and claro-cellular carcinoma with sarcomatoid features in the non-responder. The number of circulating tumor cells (CTCs) was evaluated longitudinally to monitor disease dynamics. Beside the decreased number of CTCs after MitoTam administration, we observed a significant decrease of the mitochondrial network mass in enriched CTCs. Two patients had long-term clinical responses to MitoTam, of 50 and 36 weeks. Both patients discontinued treatment due to adverse events, not PD. Two patients who completed the trial in November 2019 and May 2020 are still alive without subsequent anticancer therapy. The toxicity of MitoTam increased with the dosage but was manageable. The efficacy of MitoTam in pretreated ccRCC patients is linked to the novel mechanism of action of this first-in-class mitochondrially targeted drug.

References

Gagnier J, Kienle G, Altman D, Moher D, Sox H, Riley D . The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development. Glob Adv Health Med. 2014; 2(5):38-43. PMC: 3833570. DOI: 10.7453/gahmj.2013.008. View

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

Scher H, Jia X, de Bono J, Fleisher M, Pienta K, Raghavan D . Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3):233-9. PMC: 2774131. DOI: 10.1016/S1470-2045(08)70340-1. View

Gogvadze V, Orrenius S, Zhivotovsky B . Mitochondria in cancer cells: what is so special about them?. Trends Cell Biol. 2008; 18(4):165-73. DOI: 10.1016/j.tcb.2008.01.006. View

Hubackova S, Davidova E, Rohlenova K, Stursa J, Werner L, Andera L . Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2. Cell Death Differ. 2018; 26(2):276-290. PMC: 6329828. DOI: 10.1038/s41418-018-0118-3. View

Courtney K, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk A . Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. Cell Metab. 2018; 28(5):793-800.e2. PMC: 6221993. DOI: 10.1016/j.cmet.2018.07.020. View

Aprille J . Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev. 2001; 49(1-2):63-70. DOI: 10.1016/s0169-409x(01)00125-9. View

Liu M, Janni W, Georgoulias V, Yardley D, Harbeck N, Wei X . First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial. Cancer Manag Res. 2019; 11:10427-10433. PMC: 6913260. DOI: 10.2147/CMAR.S208712. View

Paoletti C, Hayes D . Circulating Tumor Cells. Adv Exp Med Biol. 2016; 882:235-58. DOI: 10.1007/978-3-319-22909-6_10. View

10.

Alistar A, Morris B, Desnoyer R, Klepin H, Hosseinzadeh K, Clark C . Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017; 18(6):770-778. PMC: 5635818. DOI: 10.1016/S1470-2045(17)30314-5. View

11.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

12.

Bajzikova M, Kovarova J, Coelho A, Boukalova S, Oh S, Rohlenova K . Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. Cell Metab. 2018; 29(2):399-416.e10. PMC: 7484595. DOI: 10.1016/j.cmet.2018.10.014. View

13.

Robertson-Tessi M, Gillies R, Gatenby R, Anderson A . Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res. 2015; 75(8):1567-79. PMC: 4421891. DOI: 10.1158/0008-5472.CAN-14-1428. View

14.

Du F, Yang L, Liu J, Wang J, Fan L, Duangmano S . The role of mitochondria in the resistance of melanoma to PD-1 inhibitors. J Transl Med. 2023; 21(1):345. PMC: 10207731. DOI: 10.1186/s12967-023-04200-9. View

15.

Roth K, Mambetsariev I, Kulkarni P, Salgia R . The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends Mol Med. 2019; 26(1):119-134. PMC: 6938552. DOI: 10.1016/j.molmed.2019.06.009. View

16.

Marquardt A, Solimando A, Kerscher A, Bittrich M, Kalogirou C, Kubler H . Subgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. Front Oncol. 2021; 11:621278. PMC: 8005734. DOI: 10.3389/fonc.2021.621278. View

17.

Bielcikova Z, Stursa J, Krizova L, Dong L, Spacek J, Hlousek S . Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial. EClinicalMedicine. 2023; 57:101873. PMC: 10102891. DOI: 10.1016/j.eclinm.2023.101873. View

18.

Miyazono Y, Hirashima S, Ishihara N, Kusukawa J, Nakamura K, Ohta K . Uncoupled mitochondria quickly shorten along their long axis to form indented spheroids, instead of rings, in a fission-independent manner. Sci Rep. 2018; 8(1):350. PMC: 5762872. DOI: 10.1038/s41598-017-18582-6. View

19.

Wallwiener M, Riethdorf S, Hartkopf A, Modugno C, Nees J, Madhavan D . Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer. 2014; 14:512. PMC: 4226959. DOI: 10.1186/1471-2407-14-512. View

20.

Stemberkova-Hubackova S, Zobalova R, Dubisova M, Smigova J, Dvorakova S, Korinkova K . Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy. Clin Transl Med. 2022; 12(3):e645. PMC: 8964933. DOI: 10.1002/ctm2.645. View